FOI 2024-036

Response below is for the time period 01/10/2023 to 31/03/2024 inclusive:

Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

90

Q2. Of the multiple myeloma patients over the past 6 months, how many were treated with the following:

·       Belantamab Mafodotin [Blenrep] - <5

·       Bortezomib [Velcade] monotherapy or with dexamethasone - NIL

·       Bortezomib, thalidomide and dexamethasone [VTD] - NIL

·       Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd) - 6

·       Carfilzomib [Kyprolis] and dexamethasone – NIL

·       Carfilzomib [Kyprolis], Lenalidomide [Revlmid] and dexamethasone - 6

·       Daratumumab [Darzalex] monotherapy - <5

·       Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd) - 7

·       Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd) - 10

·       Daratamumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone - <5

·       Elranatamab - NIL

·       Idecabtagene vicleucel [Abecma] - NIL

·       Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd) - <5

·       Ixazomib [Ninlaro], Lenalidomide [Revlmid] and dexamethasone (known as IRd) - 5

·       Lenalidomide [Revlmid] monotherapy - 18

·       Lenalidomide [Revlimid] and dexamethasone - 22

·       Pomalidomide [Imnovid] and dexamethasone - NIL

·       Selinexor and dexamethasone - NIL

·       Talquetamab - NIL

·       Teclistamab [Tecvayli] - NIL

·       Any other systemic anti-cancer therapy – 8